Louisiana high court tosses $257M Risperdal verdict for lack of evidence

Johnson & Johnson ($JNJ) persuaded the Louisiana Supreme Court to toss a $257 million verdict against the company in a Risperdal marketing case, a big win in the company's multibillion-dollar fight with state and federal authorities. A Louisiana jury had held J&J liable for deceptively marketing Risperdal, a powerful antipsychotic drug, to doctors in the state, but the justices determined that the state hadn't presented sufficient evidence to show J&J had duped doctors into prescribing Risperdal over rival drugs. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.